CAMK2G and myeloid leukemia: Inhibition or knockdown of CaMKI, CaMKII, or CaMKIV reduces proliferation in different myeloid leukemia cells and multiple CAMK or calmodulin antagonists have been used to inhibit leukemic cell growth and proliferation (269, 270, 305–307).